16.84
+2.93%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Selvita
Its shares trade on GPW under the ticker SLV.WA. It has been listed since 16 October 2019. In the fiscal year to 31 December 2025, it reported revenue of PLN 364.5m and net income of PLN 813,000. At that date it held total assets of PLN 597.8m and shareholders' equity of PLN 321.7m.
Selvita SA engages in the discovery, regulatory studies, as well as research and development. The company is headquartered in Krakow, Woj. Malopolskie. The company went IPO on 2019-10-16. The firm is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. The company offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The firm cooperates with numerous research institutes and universities from Europe and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 16 Oct 2019
- Employees
- 889
- Website
- selvita.com ↗
Leadership
Pay as last reported
- Dr. Piotr RomanowskiIndependent Chairman of the Supervisory BoardPLN 8.0m
- Mr. Boguslaw SieczkowskiPresident of the Management BoardPLN 13.8m
- Dr. Tadeusz WesolowskiIndependent Vice Chairman of the Supervisory BoardPLN 6.9m
- Dr. Milosz GrucaVice President of the Management BoardPLN 840,300
- Mr. Darius KurdasMember of the Management BoardPLN 13.3m
- Mr. Paul OvertonMember of the Management Board
- Mr. Dawid RadziszewskiMember of the Management BoardPLN 543,000
- Dr. Adrijana VinterMember of the Management Board, since 2022
- Mr. Wojciech ChabasiewiczIndependent Member of the Supervisory BoardPLN 6.0m
- Mr. Rafal ChwastIndependent Member of the Supervisory BoardPLN 6.0m
- Mr. Jacek OsowskiMember of the Supervisory BoardPLN 5.9m
- Mr. Pawel PrzewiezlikowskiMember of the Supervisory BoardPLN 6.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Selvita SA employs 889 full-time employees in Krakow, Poland, supporting drug discovery and regulatory studies.
- The company provides multidisciplinary solutions for drug discovery from target validation to clinical candidate selection.
- Selvita SA collaborates with research institutes and universities across Europe and the United States.
Weaknesses
- Selvita SA's headquarters in Krakow, Poland, may limit access to global markets.
- The company's IPO on 16 October 2019 might indicate limited financial history.
- Selvita SA's focus on drug discovery could restrict diversification into other health care sectors.
Opportunities
- Selvita SA can expand its services to the growing Life Sciences Tools & Services industry in Europe.
- Collaboration with European research institutions offers potential for new drug discovery projects.
- The company may leverage its expertise in bioanalytical analyses to enter new markets.
Threats
- Competition from established players in the Life Sciences Tools & Services sector could impact Selvita SA's market share.
- Regulatory changes in the Health Care industry might increase compliance costs for Selvita SA.
- Economic downturns in Europe could reduce funding for drug discovery projects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.